fast-acting insulin

Fast-acting insulin is a recombinant insulin analog developed by Chongqing Chenan Biological Pharmaceutical for the treatment of diabetes mellitus. It acts as an insulin receptor agonist, mimicking the physiological action of endogenous insulin by binding to the insulin receptor. This binding promotes cellular glucose uptake in muscle and adipose tissue while simultaneously inhibiting hepatic glucose production, thereby lowering blood glucose levels. As a fast-acting analog, it is designed to have a rapid onset of action following subcutaneous injection, making it suitable for prandial (mealtime) glucose control to manage postprandial blood sugar spikes. This candidate is part of Chenan Bio's broader portfolio of insulin products, which includes long-acting and biphasic formulations aimed at providing comprehensive diabetes management solutions.

Other names

速效胰岛素